{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:28:38Z","timestamp":1761182918948,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jiac.2017.08.010","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T11:33:49Z","timestamp":1508758429000},"page":"820-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug resistance"],"prefix":"10.1016","volume":"23","author":[{"given":"Young Seok","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Wook","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Global tuberculosis report 2016","author":"World Health Organization","key":"10.1016\/j.jiac.2017.08.010_bib1"},{"year":"2010","series-title":"Multidrug and extensively drug-resistant TB (M\/XDR-TB): 2010 global report on surveillance and response","author":"World Health Organization","key":"10.1016\/j.jiac.2017.08.010_bib2"},{"key":"10.1016\/j.jiac.2017.08.010_bib3","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","article-title":"Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis","volume":"375","author":"Gandhi","year":"2010","journal-title":"Lancet (Lond Engl)"},{"key":"10.1016\/j.jiac.2017.08.010_bib4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1164\/rccm.200911-1656OC","article-title":"Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis","volume":"182","author":"Kim","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1056\/NEJMra0908076","article-title":"MDR tuberculosis\u2013critical steps for prevention and control","volume":"363","author":"Nathanson","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1164\/rccm.200911-1768OC","article-title":"Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment","volume":"182","author":"Shin","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2017.08.010_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2017.08.010_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cit643","article-title":"Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis","volume":"58","author":"Shah","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1604544","article-title":"Transmission of extensively drug-resistant tuberculosis in South Africa","volume":"376","author":"Shah","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3346\/jkms.2007.22.1.26","article-title":"The interval between initiation of anti-tuberculosis treatment in patients with culture-positive pulmonary tuberculosis and receipt of drug-susceptibility test results","volume":"22","author":"Joh","year":"2007","journal-title":"J\u00a0Korean Med Sci"},{"year":"2016","series-title":"The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin","author":"World Health Organization","key":"10.1016\/j.jiac.2017.08.010_bib12"},{"year":"2016","series-title":"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance","author":"World Health Organization","key":"10.1016\/j.jiac.2017.08.010_bib13"},{"key":"10.1016\/j.jiac.2017.08.010_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4046\/trd.2012.73.1.48","article-title":"The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in korea","volume":"73","author":"Park","year":"2012","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.jiac.2017.08.010_bib15","unstructured":"Hain lifescience GmbH. Genotype mtbdrsl molecular genetic assay for identification of resistances to fluoroquinolones, aminoglycosides\/cyclic peptides and ethambutol of the mycobacterium tuberculosis complex. http:\/\/www.hain-lifescience.de\/en\/downloads\/microbiology.html [Accessed 17.6.3]."},{"key":"10.1016\/j.jiac.2017.08.010_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/23744235.2015.1125999","article-title":"Evaluation of the genotype(r) MTBDRsl assay in Korean patients with mdr or xdr tuberculosis","volume":"48","author":"Jeong","year":"2016","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.jiac.2017.08.010_bib17","first-page":"571","article-title":"Trend of anti-tuberculosis drug resistance in korea, 1994\u20132004","volume":"11","author":"Bai","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib18","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1164\/rccm.201303-0604OC","article-title":"Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis","volume":"188","author":"Koh","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"year":"2014","series-title":"Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis","author":"WHO guidelines approved by the guidelines review committee","key":"10.1016\/j.jiac.2017.08.010_bib19"},{"key":"10.1016\/j.jiac.2017.08.010_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib21","article-title":"Genotype(r) MTBDRsl assay for resistance to second-line anti-tuberculosis drugs","volume":"9","author":"Theron","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2017.08.010_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039754","article-title":"New insights into fluoroquinolone resistance in mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations","volume":"7","author":"Malik","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2017.08.010_bib23","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2017.08.010_bib24","first-page":"535","article-title":"Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant mycobacterium tuberculosis isolates","volume":"133","author":"Singh","year":"2011","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jiac.2017.08.010_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1471-2334-13-240","article-title":"Detection of second-line drug resistance in mycobacterium tuberculosis using oligonucleotide microarrays","volume":"13","author":"Zimenkov","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120470","article-title":"Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical mycobacterium tuberculosis isolates: a systematic review","volume":"10","author":"Avalos","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jiac.2017.08.010_bib27","first-page":"99","article-title":"Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa","volume":"12","author":"Mlambo","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.5588\/ijtld.14.0488","article-title":"Phenotypic and genotypic diversity in a multinational sample of drug-resistant mycobacterium tuberculosis isolates","volume":"19","author":"Garfein","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jiac.2014.12.009","article-title":"Performance of REBA MTB-XDR to detect extensively drug-resistant tuberculosis in an intermediate-burden country","volume":"21","author":"Lee","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2017.08.010_bib30","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1128\/AAC.00425-16","article-title":"Moxifloxacin improves treatment outcomes in patients with ofloxacin-resistant multidrug-resistant tuberculosis","volume":"60","author":"Chien","year":"2016","journal-title":"Antimicrob Abents Chemother"},{"key":"10.1016\/j.jiac.2017.08.010_bib31","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1128\/AAC.00968-10","article-title":"Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model","volume":"54","author":"Poissy","year":"2010","journal-title":"Antimicrob Abents Chemother"},{"key":"10.1016\/j.jiac.2017.08.010_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/mdr.2006.12.7","article-title":"Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant mycobacterium tuberculosis: correlation with ofloxacin susceptibility","volume":"12","author":"Kam","year":"2006","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jiac.2017.08.010_bib33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/jac\/dks033","article-title":"gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of mycobacterium tuberculosis","volume":"67","author":"Sirgel","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2017.08.010_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5588\/ijtld.13.0307","article-title":"Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis","volume":"18","author":"Jo","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jiac.2017.08.010_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/MCP.0000000000000045","article-title":"Tuberculosis: clinical trials and new drug regimens","volume":"20","author":"Kwon","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jiac.2017.08.010_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00162314","article-title":"Novel drugs against tuberculosis: a clinician's perspective","volume":"45","author":"Olaru","year":"2015","journal-title":"Eur Respir J"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X17301897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:56:13Z","timestamp":1761159373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X17301897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1341321X17301897"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2017.08.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of the GenoType MTBDRsl assay for the detection second-line anti-tuberculosis drug resistance","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2017.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}